Sir,

We would like to thank the reader for showing the interest on reading our article titled "Revised National Tuberculosis Control Program (RNTCP) regimens with and without directly observed treatment, short-course: A comparative study of therapeutic cure rate and adverse reactions" published in Perspectives in Clinical Research.\[[@ref1]\] Due to the ethical consideration and treatment modality we excluded the subjects who has diabetes mellitus, human immunodeficiency virus (HIV) infection, extra-pulmonary tuberculosis (TB), bronchial asthma and pregnant women, children below 11 years of age. If we included the patient with diabetes mellitus, HIV infection, extra-pulmonary TB, bronchial asthma and pregnant women, children below 11 years of age the treatment protocol and repeated visit to the "TB and chest clinic" may affect their quality of life.

In this study, 60 patients affected with pulmonary TB and receiving the RNTCP\'s directly observed treatment, short-course (DOTS) regimen (group-I) and 65 patients with pulmonary TB receiving the RNTCP\'s non-DOTS regimen (group-II) were interviewed and included whoever met the inclusion criteria, were included in the study with their consent. Then the study subjects where followed-up for next 6 months and monitored for the drug induced events/toxicity. We are strongly agreed the reader point related to the socio-economic status of the patient will affect the study outcome. In part of the study, we analyzed the socio-economic status of all study participants. Most subjects from the rural part of the Cuddalore District, Tamil Nadu and they are in the category of the low- and medium-income levels.\[[@ref2]\] The demographic distribution of the study subjects were already presented in Table 1.\[[@ref1]\]

Since the study was the post-graduate thesis, the clinical phase of the study was 8 months which excluding protocol preparation, data analysis and presentation. The study was conducted between June 2003 and February 2006 including protocol preparation, obtaining Ethics Committee permission, incorporation of modifications suggested by Ethics Committee, clinical phase of the study (8 months) and data-analysis.

At the end of the study, we achieved the objective of the study by compare the therapeutic cure rate and adverse reactions in the regimens of the RNTCP with DOTS and without DOTS. In our further studies, we will incorporate the recommendations of the DOTS-Plus guidelines (January 2010), Central TB Division, Directorate General of Health Services, Ministry of Health and Family Welfare, New Delhi, India.\[[@ref3]\]
